Bioxytran BIXT
OTC BIXT
$0.02 +0.00 (+0.00%)
At close: Sep 29, 2026 · 4:00 PM EDT

Bioxytran (BIXT) Accumulated Expenses (2013 - 2026)

Updated

Bioxytran (BIXT) recorded Accumulated Expenses of $843,615 in Q2 2026, up 167.8% from the prior quarter.

Analysis

Bioxytran (BIXT) Accumulated Expenses (2013 - 2026) Analysis & Trends

At the end of FY2025, Bioxytran reported Accumulated Expenses of $577,500.

  • Across earlier years, Accumulated Expenses came in at $223,759 in FY2023.
  • The Q2 2026 figure is the highest quarterly Accumulated Expenses in data going back to Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Bioxytran 2.29 Mn 1.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 843,615.00
Mar 31, 2026 315,000.00
Dec 31, 2025 577,500.00
Sep 30, 2024 126,286.00
Dec 31, 2023 223,759.00
Jun 30, 2018 28,476.00
Mar 31, 2018 26,526.00
Dec 31, 2017 24,576.00
Sep 30, 2017 32,626.00
Jun 30, 2017 30,676.00
Mar 31, 2017 28,725.00
Dec 31, 2016 26,776.00
Sep 30, 2016 31,826.00
Jun 30, 2016 29,876.00
Mar 31, 2016 27,926.00
Dec 31, 2015 25,976.00
Sep 30, 2015 19,003.00
Jun 30, 2015 27,044.00
Mar 31, 2015 25,099.00
Dec 31, 2014 23,176.00
API Access

Bioxytran Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=BIXT&period=max&api_key=YOUR_API_KEY